Jyong Biotech Ltd (MENS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Jyong Biotech Ltd (MENS) is down 59.8% since the beginning of the year. At $2 per share, MENS is trading 97.6% below its 52-week high of $67.

Jyong Biotech Ltd (MENS) has returned -59.75% so far this year and -80.15% over the past 12 months.

Based on dividend-adjusted daily data since Jun 17, 2025, MENS's average daily return is -0.05%, while the average monthly return is +4.23%. At this rate, an investment would double in approximately 1.4 years.

Historically, 38% of months were positive and 62% were negative. The best month was Aug 2025 with a return of +187.6%, while the worst month was Dec 2025 at -85.5%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, MENS closed higher 46% of trading days. The best single day was Dec 30, 2025 with a return of +51.8%, while the worst single day was Dec 17, 2025 at -81.0%.

Jyong Biotech Ltd has an annualized alpha of -48.38%, beta of 2.48, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 17, 2025.

• This stock participated in 491.46% of S&P 500 Index downside but only 31.25% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MENS ranks 26 for risk / return — below 26% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Jyong Biotech Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jyong Biotech Ltd was 97.78%, occurring on Feb 11, 2026. The portfolio has not yet recovered.

The current Jyong Biotech Ltd drawdown is 97.58%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Jyong Biotech Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Jyong Biotech Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.